| Muscle Nerve. 2002 Oct;26(4):549-52. |
|
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ; Myasthenia Gravis-IVIG Study Group.
Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390-8897,USA.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed. Copyright 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 549-552, 2002
Publication Types:
- Clinical Trial
- Randomized Controlled Trial
PMID: 12362423 [PubMed - indexed for MEDLINE]
|
